Peptide ScheduleWeight Loss Stack
Combine GLP-1 appetite suppression with targeted fat metabolism. Semaglutide reduces hunger at the brain level while AOD-9604 specifically targets fat breakdown without affecting blood sugar or growth.
Semaglutide
Semaglutide is a GLP-1 receptor agonist — the same active ingredient in Ozempic and Wegovy. It mimics the hormone GLP-1, which regulates appetite and blood sugar. By slowing gastric emptying and acting on brain satiety centers, it dramatically reduces hunger and caloric intake. FDA-approved for both type 2 diabetes and obesity.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 250mcg | Weekly |
| Moderate | 500mcg | Weekly |
| Aggressive | 1mg | Weekly |
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) specifically designed for fat metabolism. Unlike full HGH, it stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood sugar or growth. It has GRAS (Generally Recognized As Safe) status in the US.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 300mcg | Daily |
| Aggressive | 500mcg | Daily |
Protocol Tips
- Titrate Semaglutide slowly — start at 250mcg/week.
- AOD-9604 should be dosed on an empty stomach.
- Prioritize protein intake to preserve lean muscle.
- See our GLP-1 titration tool for the full Semaglutide schedule.